文献速递银屑病与炎症性皮肤病

Spesolimab减轻泛发性脓疱型银屑病炎症:EFFISAYIL 1 flare治疗的分子特征

Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1.
PubMed 文献 · J Invest Dermatol · 2024-07-14

EFFISAYIL 1是一项随机、安慰剂对照研究,评估抗IL-36受体抗体spesolimab治疗泛发性脓疱型银屑病 flare 的疗效。治疗约半数患者脓疱和皮损清除更快。本研究对皮损和非皮损皮肤及全血样本进行组织学、转录组和蛋白质组分析,显示spesolimab使皮肤基因表达向非皮损profile转变,下调IL-36转录本及中性粒细胞招募、促炎细胞因子和皮肤炎症相关基因,变化在第1周显现并持续至第8周;血清炎症生物标志物(IL-17、IL-8、IL-6)下降持续至治疗后12周。皮肤和血液样本中spesolimab诱导的基因和蛋白质表达变化有相当程度重叠,证明其控制局部和全身炎症的分子基础。

要点

  • spesolimab治疗使GPP flare皮肤基因表达向非皮损profile转变,第1周即显现并持续至第8周
  • 皮肤中IL-36转录本(IL36α、IL36β、IL36γ)及中性粒细胞招募相关基因(CXCL1、CXCL6、CXCL8)下调
  • 血清炎症生物标志物(IL-17、IL-8、IL-6)下降持续至spesolimab治疗后12周

核心结论

  • spesolimab通过抑制IL-36通路,导致GPP flare相关的关键局部和全身病理事件减少,分子数据与其作用机制一致。

研究设计与样本

  • EFFISAYIL 1随机、安慰剂对照研究,对收集的皮损和非皮损皮肤及全血样本进行组织学、转录组和蛋白质组分析。

主要发现

  • spesolimab治疗使皮肤基因表达向非皮损profile转变,下调IL-36转录本和中性粒细胞招募、促炎细胞因子及皮肤炎症相关基因。
  • 皮肤基因表达变化在第1周显现并持续至第8周。
  • 血清炎症生物标志物(IL-17、IL-8、IL-6)下降持续至spesolimab治疗后12周。
  • 皮肤和血液样本中spesolimab诱导的基因和蛋白质表达变化有相当程度重叠。

关键数值与推荐

  • 皮肤中IL-36转录本(IL36α、IL36β、IL36γ)及中性粒细胞招募相关基因(CXCL1、CXCL6、CXCL8)、促炎细胞因子(IL6、IL19、IL20)和皮肤炎症相关基因(DEFB4A、S100A7、S100A8)表达下调。

临床怎么用

  • spesolimab可快速控制GPP flare的局部和全身炎症,分子证据支持其用于flare治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

EFFISAYIL 1 was a randomized, placebo-controlled study of spesolimab, an anti-IL-36 receptor antibody, in patients presenting with a generalized pustular psoriasis flare. Treatment with spesolimab led to more rapid pustular and skin clearance versus treatment with placebo in approximately half of the patients. In this study, we present histologic, transcriptomic, and proteomic analyses of lesional and nonlesional skin and whole-blood samples collected from EFFISAYIL 1. Treatment with spesolimab led to a transition toward a nonlesional profile, with a downregulation of gene expressions in the skin of IL-36 transcripts (IL36α, IL36β, IL36γ) and those associated with neutrophil recruitment (CXCL1, CXCL6, CXCL8), proinflammatory cytokines (IL6, IL19, IL20), and skin inflammation (DEFB4A, S100A7, S100A8). Changes were manifest at week 1 and sustained to week 8. At the systemic level, reductions in serum biomarkers of inflammation (IL-17, IL-8, IL-6) were sustained until 12 weeks after spesolimab treatment. Considerable overlap was observed in the spesolimab-induced changes in gene and protein expressions from skin and blood samples, demonstrating the molecular basis of the effects of spesolimab on controlling local and systemic inflammation. Data are consistent with the mode of action of spesolimab, whereby inhibition of the IL-36 pathway leads to subsequent reductions in the key local and systemic pathologic events associated with generalized pustular psoriasis flares.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Farag A, Visvanathan S, Bachelez H, et al. Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1. J Invest Dermatol. 2024. PMID: 39004117. doi:10.1016/j.jid.2024.05.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。